Trade Summary

5 days ago, Kunkel Lori Anne, serving as Dir at Enliven Therapeutics, Inc. (ELVN), sold 10,000 shares at $34.54 per share, for a total transaction value of $345,351.35. Following this transaction, Kunkel Lori Anne now holds 51,884 shares of ELVN.

This sale represents a 16.16% decrease in Kunkel Lori Anne's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, June 5, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, June 9, 2026 at 4:49 PM ET, 4 days after the trade was made.

Enliven Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.